About - Scailyte

“True precision medicine through single-cell science.”

Our new and emerging analytical device produces rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection, but it requires sophisticated and innovative computational approaches in order to extract the relevant information.

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human’s hidden “single-cell” secrets. The performance and clinically-relevant application of Scailyte’s platform ScaiVision have been demonstrated in numerous clinical projects that resulted in patent-pending biomarkers. Scailyte has a growing pipeline of clinical projects in immunology, oncology and women’s health supported by top clinicians and access to high-quality proprietary datasets.

We are addressing this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying best-in-class algorithms allow us to associate patterns in single-cell data with disease status.

We provide a powerful software solution (ScaiVision), unifying our AI technology for the global medical community and delivering it to those working in drug and diagnostic R&D.

To save lives by enabling precision medicine.

Dr. Peter Nestorov

Founder & Chief Executive Officer

Peter holds a PhD in Genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen. He has been working in the emerging single-cell analysis market since 2015 and this gave him the inspiration to start Scailyte as co-founder and CEO in 2017.

Dr. Sarah Carl

Director Data Science

Sarah holds a PhD in Genetics from the University of Cambridge. She worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte. Sarah joined Scailyte as a data scientist in 2018 and has been recently promoted to become Director of Data Science.

Dr. Andrius Serva

Director Corporate Development

Andrius obtained a PhD in Systems Biology from Heidelberg University in Germany and continued as researcher in oncology at the German Cancer Research Center (DKFZ) in Heidelberg. After working for single-cell biotech Fluidigm, he joined Scailyte in 2019 and has been recently promoted to lead the Corporate Development team.

Anna Dimitrova, ACCA

Director Finance & Operations

Anna is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Previously, she worked as a finance manager in a fast growing company, auditor in KPMG and business consultant in PwC. Anna joined the Scailyte team in 2018.

Prof. Dr. Manfred Claassen

Founder & Chief Scientific Advisor AI & Single-Cell Analysis

He holds degrees in both Biochemistry and Computer Science from the University of Tübingen and a PhD in the design and validation of proteome measurements from the ETH Zurich.

Prof. Dr. Michael Mueller, MD

Clinical Advisor Endometriosis

is a renowned gynecologist and gynecological oncologist, and managing director of the Women’s Health Clinic at the University Hospital of Bern (Inselspital). Prof. Mueller is supporting Scailyte as a clinical advisor and expert in endometriosis and women’s health.

Prof. Dr. Petter Brodin, MD

is a pioneer in single-cell analysis and, advising Scailyte in immunology and the application of single-cell technologies for clinical research. Prof. Brodin is based at the Karolinska Institute in Sweden and heads a research group that focuses on systems-level analyses of the human immune system. Prof. Brodin is a consultant pediatrician working at the Karolinska University Hospital.

Prof. Dr. Emmanuella Guenova, MD

Clinical Advisor CTCL & Immunology

is a dermatologist, specialist in cutaneous lymphoma and laboratory diagnostics of skin diseases, and appointed professor at the Faculty of Biology and Medicine of the University of Lausanne.

Dr. Michael Stadler

received training in immunology and bioinformatics from the Universities of Lausanne and Geneva. He is a scientific advisor supporting Scailyte’s with the development of our data analytics platform.

Prof. Dr. Tomas Kalina MD

Scientific Advisor Flow Cytometry & Immuno assays

is a physician and a cytometry expert currently leading a research group focused on disorders of adaptive immunity at the Charles University in Prague. Professor Kalina is supporting Scailyte as a clinical diagnostic advisor with his expertise in cytometry standardization.

Pascal Koenig

Co-Founder Ava Women & Scailyte Chair of the Board of Directors

Pascal is a co-founder and member of the board of Ava Women, big data and artificial intelligence firm in women’s health with offices in Switzerland and the USA.

Dominique Mégret

Head of Swisscom Ventures & Scailyte Board of Directors

Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit.

Michael Brenner

Professor of Medicine at Harvard Medical School & Scailyte Advisor to Board of Directors

Prof. Brenner is the director of Brigham and Women’s Hospital’s Human Immunology Center, which creates and performs single-cell transcriptional analysis and functional investigations.

Jean-Pierre Rosat

Founder 4FO Venture Partners & Scailyte Board of Directors

Jean-Pierre Rosat is managing partner and founder of 4FO Venture Partners, which he started in 2015.

Pascal Winnen

CEO Hemex AG & Scailyte Board of Directors

Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA.

Jean-Pierre Rosat

Founder 4FO Venture Partners & Scailyte Board of Directors

Jean-Pierre Rosat is managing partner and founder of 4FO Venture Partners, which he started in 2015.

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

To achieve our mission, we are looking for smart, passionate and dedicated individuals who share our values, by dreaming big, to join our growing, energetic and fun team. We offer flexible working schedules and home-office options

Recent News

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Scailyte Quarterly Update, April 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Recent News

01 /04

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Recent News

02 /04

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Recent News

03 /04

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Scailyte Quarterly Update, April 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Recent News

04 /04

Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Our mission is to discover and develop biomarkers for precision medicine using single-cell data and Artificial Intelligence.

About us

Vision